Back to search results

Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

Abroad (travel likely)RecruitingPHASE1

Conditions

Advanced Solid Tumors

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado, United States

    Contact: Study coordinator (Ashley Fisher) · ASHLEY.R.FISHER@CUANSCHUTZ.EDU
    Contact: Principal Investigator (Antonio Jimeno)

  • Sarah Cannon Research Institute (SCRI) at HealthONE, Denver, Colorado, United States

    Contact: Study coordinator (Jason Henry) · Jason.Henry2@sarahcannon.com
    Contact: Principal Investigator (Jason Henry)

  • Yale School of Medicine - Yale Cancer Center - Smilow Cancer Hospital Care Centers - North Haven, North Haven, Connecticut, United States

    Contact: Study coordinator (Anastasio Gabrielle) · gabrielle.anastasio@yale.edu
    Contact: Principal Investigator (Michael Cecchini)

  • Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida, United States

    Contact: Study coordinator (Elizabeth Gilmore) · Elizabeth.Griffith@scri.com
    Contact: Principal Investigator (Cesar Perez)

  • Florida Cancer Specialists & Research Institute (FCS) - Sarasota Cattlemen Office, Sarasota, Florida, United States

    Contact: Study coordinator (Carly Taylor) · ctaylor@flcancer.com
    Contact: Principal Investigator (Manish Patel)

  • Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley, Las Vegas, Nevada, United States

  • University of Cincinnati Vontz Center for Molecular Studies, Cincinnati, Ohio, United States

  • The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Coordinator Clinical operation director) · RA@medilinkthera.com

  • NEXT Oncology - Houston, Houston, Texas, United States

  • NEXT Oncology - Dallas, Irving, Texas, United States

    Contact: Study coordinator (Erica Torres) · etorres@nextoncology.com
    Contact: Principal Investigator (Shiraj Sen)

  • NEXT San Antonio, San Antonio, Texas, United States

    Contact: Study coordinator (Coordinator Clinical operation director) · RA@medilinkthera.com

  • Gosford Hospital, Gosford, New South Wales, Australia

  • One Clinical Research - Nedlands, Nedlands, Western Australia, Australia

  • Monash Health, Melbourne, Australia

    Contact: Study coordinator (Sophia Frentzas) · sophia.frentzas@monash.edu
    Contact: Principal Investigator (Sophia Frentzas)

  • Princess Margaret Hospital, Toronto, Toronto, Canada

    Contact: Study coordinator (Albiruni Razak) · Albiruni.razak@uhn.ca
    Contact: Principal Investigator (Albiruni Razak)

  • The Ottawa Hospital - General Campus, Ottawa, Canada

    Contact: Study coordinator (Jura Nakamura) · junakamura@ohri.ca
    Contact: Principal Investigator (Scott Laurie)

  • China-Japan Friendship Hospital, Beijing, Beijing Municipality, China

  • The First Affiliated Hospital - Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

  • Wenzhou Medical University - The First Affiliated Hospital, Wenzhou, Zhejiang, China

  • West China Hospital, Sichuan University, Chengdu, China

    Contact: Study coordinator (Yan Zhang) · 18980601166@qq.com
    Contact: Principal Investigator (Yan Zhang)

  • Sun Yat-sen University Cancer Center, Guangzhou, China

    Contact: Study coordinator (Danyun Ruan) · ruandy1@sysucc.org.cn
    Contact: Principal Investigator (Ruihua Xu)
    Danyun Ruan (Sub-investigator)
View source on ClinicalTrials.gov(opens in a new tab)